Neophore, a Cambridge, UK-based small molecule neoantigen immuno-oncology company, raised an undisclosed amount in Series B extension funding.
Bristol Myers Squibb (NYSE: BMY) made the investment.
The company intends to use the funds to explore novel biology associated with the DNA mismatch repair (‘MMR’) pathway in cancer, as well as further progress its pre-clinical studies and deliver a candidate drug in 2025.
Led by CEO Dr Matthew Baker, NeoPhore is focused on building a pipeline of small molecule drugs targeting novel proteins across the MMR pathway to generate immuno-oncology therapeutics to improve clinical outcomes for cancer patients. Its MMR inhibitors induce neoantigen expression and increase immunogenicity in solid tumours that become exquisitely sensitive to immunotherapy.
NeoPhore was spun-out of the University of Turin and PhoreMost Ltd by the CRT Pioneer Fund.
FinSMEs
22/05/2024